Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers

Executive Summary

Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside  Medicare's reimbursement bundle for end-stage renal disease.

Advertisement

Related Content

US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best
Phase III Roxadustat ALPS Data Positive For New Class Of Anemia Therapies
Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs
Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel